Patients With “Gray Zone” PSA Levels: Application of Prostate MRI and MRS in the Diagnosis of Prostate Cancer

Abstract

Improving the detection rates of prostate cancer (PCa) and avoiding unnecessary prostate biopsies in men with prostate‐specific antigen (PSA) levels within the gray zone require urgent attention. In this context, rapid advances in MR technology in recent years may offer a promising possibility. A systematic review to evaluate the applications of magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) in detecting PCa and clinically significant PCa (csPCa) in men with PSA levels within the gray zone. The study type is defined as systematic review. In July 2022, out of 229 studies identified by the database search and from other sources, 23 articles related to the selected topic of interest were included in this review. No field strength or sequence restrictions. The data including the study population, study characteristics, as well as basic MRI characteristics, from the final studies included in this review, were extracted independently by two reviewers. The major results of the original study were summarized and no additional statistical analysis was performed. Among the 23 studies included in this review, 17 focused on the applications of MRS and MRI for the prebiopsy diagnosis of PCa. Nine of these 17 articles used Prostate Imaging Reporting and Data System (PI‐RADS) score to interpret MRI results, thereby confirming the practicality of the PI‐RADS score in predicting PCa and csPCa. The remaining six articles evaluated the applications of MRI and MRS in guiding prostate biopsy. Although there was a variation in the biopsy modalities used in these studies, both MRI‐ and MRS‐guided prostate biopsies were observed to improve the detection rates of PCa and csPCa in patients with PSA levels within the gray zone. MRS and MRI showed good performance in the detection of PCa and csPCa before biopsy. In addition, MRS‐ or MRI‐guided prostate‐targeted biopsies were able to improve the detection rates of PCa and csPCa. Evidence Level 3 Technical Efficacy Stage 2

A Large Genetic Causal Analysis of the Gut Microbiota and Urological Cancers: A Bidirectional Mendelian Randomization Study

“…However, both examinations are invasive, limiting their use in large-scale screening [ 7 ]. In recent years, serum prostate-specific antigen (PSA) has been widely used for screening and early detection of prostate cancer due to its non-invasive advantages [ 69 ]. Typically, a prostate biopsy is performed when a patient’s PSA level is greater than 4 ng/mL [ 70 ].…”

Development trends and knowledge framework in the application of magnetic resonance imaging in prostate cancer: a bibliometric analysis from 1984 to 2022

“…With the development of medical imaging technology, the applications of MRI in PCa have evolved into using rich imaging sequences, dynamic enhancement, and even AI to achieve an accurate evaluation of PCa. MpMRI refers to the combination of multiple MRI sequences required to make a diagnosis, it consists of both anatomic [T1-weighted (T1W) and T2-weighted (T2W) MRI] sequences as well as functional sequences, including diffusion-weighted imaging (DWI) MRI, DCE MRI, and magnetic resonance spectroscopy (MRS) ( 31 - 33 ). Meanwhile, the PI-RADS classification as an imaging assessment based on mpMRI can provide more detailed clinical information, leading to the refinement of the clinical evaluation of PCa ( 34 ).…”

Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives

“…Thus, citrate and polyamine levels are high and choline levels low in normal prostatic tissue while they have inverted concentrations in PC [59]. MR spectroscopy is definitely a powerful instrument and can be a game changer in border-line patients [60], but a standardization of findings is needed as inter-operator variability can affect medical report repeatability.…”